News NYXH Nasdaq

Equities

NYXH

End-of-day quote Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

2022	Nyxoah's Q1 Loss Widens, Revenue Increases	MT
2022	Oppenheimer Starts Nyxoah at Outperform With $30 Price Target	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nyxoah's Q1 Loss Widens, Revenue Increases	10/22/10	MT
Oppenheimer Starts Nyxoah at Outperform With $30 Price Target	21/22/21	MT
Wolfe Research Starts Nyxoah at Peer Perform With $21 Price Target	06/22/06	MT
Piper Sandler Adjusts Price Target on Nyxoah to $30 From $40, Reiterates Overweight Rating	28/22/28	MT
NYXH : Nyxoah's Genio System Obtains CE-Mark Indication Approval to Treat Complete Concentric Collapse	05/21/05	MT
NYXH : Nyxoah Secures Breakthrough Therapy Designation for Genio Nerve Stimulation Device	14/21/14	MT
NYXH : Nyxoah Reports Wider Loss in H1	01/21/01	MT
NYXH : Stifel Initiates Nyxoah With Buy Rating	27/21/27	MT
Sector Update: Health Care Stocks Posting Gains Ahead of Friday Close	03/21/03	MT
Sector Update: Health Care	03/21/03	MT
NYXH : Belgium's Nyxoah Shares Rise in Stock Market Debut	02/21/02	MT
NYXH : Nyxoah Prices US IPO at $30 Per Share	02/21/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW